Candidate vaccine (Wuhan Institute of Biological Products and Wuhan Institute of Virology)
A COVID-19 candidate vaccine.
General information
The candidate vaccine being developed by the Beijing Institute of Biological Products/Wuhan Institute of Biological Products is an inactivated virus type of candidate vaccine. Aluminum hydroxide and MF59 are tested as adjuvants. Currently, this COVID-19 candidate vaccine is in clinical trials Phase I/II, and Phase III is being prepared.
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020
|
in vitro | Mar/26/2020 | ||
|
Draft landscape of COVID-19 candidate vaccines
|
healthy adults | Jul/28/2020 | ||
|
Low Toxicity and High Immunogenicity of an Inactivated Vaccine Candidate against COVID-19 in different animal models
Animal model In vitro Mixed substance |
Vero E6 cells; Balb/c mice; Wistar rats; Sprague Dawley (SD) rats; Hartley guinea pigs; Japanese white rabbits; Macaca fascicularis; Macaca mulatta | 5.78 | In all animal models (mice, rats, guinea pigs, rabbits, monkeys) the candidate vaccine was well tolerated and elicited strong humoral immune response. |
Nov/26/2020 |
